Inactive Instrument

News Breathtec Biomedical Inc Deutsche Boerse AG

Equities

Biotechnology & Medical Research

Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 1 million in funding	May. 27	CI
Algernon Announces $1 Mln Private Placement	May. 27	RE
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition	May. 22	AQ
Algernon Pharmaceuticals Inc. completed the acquisition of NoBrainer Imaging Centers, Inc. for CAD 0.51 million.	May. 21	CI
Algernon To Acquire Nobrainer Imaging Centers	May. 13	RE
Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology	May. 13	AQ
Algernon Pharmaceuticals Inc. entered into share exchange agreement to acquire NoBrainer Imaging Centers, Inc. for CAD 0.45 million.	May. 12	CI
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2025	Apr. 29	CI
Algernon Pharmaceuticals Brief: Says Received Notice of Allowance from European Patent Office for Repirinast for Kidney Disease	Apr. 08	MT
Algernon Pharmaceuticals Receives Notice Of Allowance From European Patent Office For Repirinast For Kidney Disease	Apr. 08	RE
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease	Apr. 08	AQ
Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing	Mar. 06	AQ
Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sandor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study	Feb. 12	AQ
Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study	Feb. 11	AQ
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare's USD $170K Equity Investment	Feb. 05	RE
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment	Feb. 05	AQ
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2024	Jan. 29	CI
Algernon Pharmaceuticals Receives U.S. Patent for Repirinast	Jan. 06	MT
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent	Jan. 06	AQ
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO for Repirinast in Kidney Disease Patent	Jan. 06	CI
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2024	Dec. 23	CI
Algernon Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	Dec. 22	CI
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.2352 million in funding	24-08-19	CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding	24-08-06	CI
Algernon Pharmaceuticals Announces Closing of Private Placement	24-08-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Breathtec Biomedical Inc Deutsche Boerse AG

Equities

Biotechnology & Medical Research

Filters